

Publications

(* corresponding/first/last author)

1. Salvi M, Borgo C, Pinna LA, **Ruzzene*** M. Targeting CK2 in cancer: a valuable strategy or a waste of time? *Cell Death Discov.* 2021 Oct 29;7(1):325. doi:10.1038/s41420-021-00717-4. PMID: 34716311; PMCID: PMC8555718.
2. Borgo C, D'Amore C, Sarno S, Salvi M, **Ruzzene*** M. Protein kinase CK2: a potential therapeutic target for diverse human diseases. *Signal Transduct Target Ther.* 2021 May 17;6(1):183. doi: 10.1038/s41392-021-00567-7. PMID: 33994545; PMCID: PMC8126563.
3. Borgo C, D'Amore C, Cesaro L, Sarno S, Pinna LA, **Ruzzene** M, Salvi M. How can a traffic light properly work if it is always green? The paradox of CK2 signaling. *Crit Rev Biochem Mol Biol.* 2021 Aug;56(4):321-359. doi:10.1080/10409238.2021.1908951. Epub 2021 Apr 11. PMID: 33843388.
4. Borgo C, **Ruzzene*** M. Protein kinase CK2 inhibition as a pharmacological strategy. *Adv Protein Chem Struct Biol.* 2021;124:23-46. doi: 10.1016/bs.apcsb.2020.09.003. Epub 2021 Jan 9. PMID: 33632467.
5. Zonta F, Borgo C, Quezada Meza CP, Masgras I, Rasola A, Salvi M, Pinna LA, **Ruzzene*** M. Contribution of the CK2 Catalytic Isoforms α and α' to the Glycolytic Phenotype of Tumor Cells. *Cells.* 2021 Jan 18;10(1):181. doi: 10.3390/cells10010181. PMID: 33477590; PMCID: PMC7831337.
6. Dalle Vedove A, Zonta F, Zanforlin E, Demitri N, Ribaldo G, Cazzanelli G, Ongaro A, Sarno S, Zagotto G, Battistutta R, **Ruzzene*** M, Lolli G. A novel class of selective CK2 inhibitors targeting its open hinge conformation. *European Journal of Medicinal Chemistry*, 2020, in press, e-pub ahead of print: <https://doi.org/10.1016/j.ejmech.2020.112267>
7. Alcaraz E, Vilardell J, Borgo C, Sarró E, Plana M, Marin O, Pinna LA, Bayascas, JR, Meseguer A, Salvi M, Itarte E, **Ruzzene*** M. Effects of CK2 β subunit down-regulation on Akt signalling in HK-2 renal cells. *PLoS One.* 2020 Jan 7;15(1):e0227340. doi: 10.1371/journal.pone.0227340. eCollection 2020. PubMed PMID: 31910234; PubMed Central PMCID: PMC6946142.
8. Cozza G, Zonta F, Dalle Vedove A, Venerando A, Dall'Acqua S, Battistutta R, **Ruzzene*** M, Lolli G. Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. *FEBS J.* 2019 Oct 29. doi: 10.1111/febs.15111. [Epub ahead of print] PubMed PMID: 31661600.
9. Di Maira G, Gentilini A, Pastore M, Caligiuri A, Piombanti B, Raggi C, Rovida E, Lewinska M, Andersen JB, Borgo C, Salvi M, Ottaviani D, **Ruzzene*** M, Marra F. The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. *Oncogenesis.* 2019 Oct 22;8(11):61. doi:10.1038/s41389-019-0171-x. PubMed PMID: 31641101; PubMed Central PMCID: PMC6805921.
10. Phosphorylation of p23-1 cochaperone by protein kinase CK2 affects root development in Arabidopsis. D'Alessandro S, Golin S, Zanin S, Cendron L, Zottini M, **Ruzzene*** M. *Sci Rep.* 2019 Jul 8;9(1):9846. doi: 10.1038/s41598-019-46327-0. IF 4.011
11. Role of protein kinase CK2 in antitumor drug resistance. Borgo C, **Ruzzene*** M. *J Exp Clin Cancer Res.* 2019 Jul 5;38(1):287. doi: 10.1186/s13046-019-1292-y
12. PreS1 Peptide-Functionalized Gold Nanostructures with SERRS tags for Efficient Liver Cancer Cell Targeting. Francesca Biscaglia, Santina Quarta, Gianmarco Villano, Cristian Turato, Alessandra Biasiolo, Lucio Litti, Maria **Ruzzene**, MorenoMeneghetti, Patrizia Pontisso, Marina Gobbo. *Materials Science & Engineering C* DOI: <https://doi.org/10.1016/j.msec.2019.109762>
13. Villamañan L, Alcaraz E, Pinna LA, **Ruzzene** M, Itarte E, Arús C, Plana M, Candiota AP. Up-Regulation of the Alpha Prime Subunit of Protein Kinase CK2 as a Marker of Fast Proliferation in GL261 Cultured Cells. *Pathol Oncol Res.* 2019 Jan 4. Epub ahead of print

14. Buontempo F, McCubrey JA, Orsini E, **Ruzzene** M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM. Therapeutic targeting of CK2 in acute and chronic leukemias. *Leukemia*. 2018 Jan;32(1):1-10.
15. Vilardell J, Girardi C, Marin O, Cozza G, Pinna LA, **Ruzzene*** M. The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131. *PLoS One*. 2018 Mar 1;13(3):e0193479.
16. Vicario M, Zanni G, Vallese F, Santorelli F, Grinzato A, Cieri D, Berto P, Frizzarin M, Lopreiato R, Zonta F, Ferro S, Sandre M, Marin O, **Ruzzene** M, Bertini E, Zanotti G, Brini M, Cali T, Carafoli E. A V1143F mutation in the neuronal-enriched isoform 2 of the PMCA pump is linked with ataxia. *Neurobiol Dis*. 2018 Jul;115:157-166.
17. Vilardell J, Alcaraz E, Sarró E, Trilla E, Cuadros T, de Torres I, Plana M, Ramón Y Cajal S, Pinna LA, **Ruzzene** M, Morote J, Meseguer A, Itarte E. Under-expression of CK2 β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. *Oncotarget*. 2017 Dec 19;9(5):5736-5751.
18. **Ruzzene*** M, Bertacchini J, Toker A, Marmioli S. Cross-talk between the CK2 and AKT signaling pathways in cancer. *Adv Biol Regul*. 2017 Mar 28. pii: S2212-4926(17)30079-9.
19. Ferrer-Font L, Villamanan L, Arias-Ramos N, Vilardell J, Plana M, **Ruzzene** M, Pinna LA, Itarte E, Arus C, Candiota AP. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. *Pharmaceuticals (Basel)*. 2017 Feb 12;10(1). pii: E24.
20. Ottaviani D, Marin O, Arrigoni G, Franchin C, Vilardell J, Sandre M, Li W, Parfitt DA, Pinna LA, Cheetham ME, **Ruzzene*** M. Protein kinase CK2 modulates HSP70 function through phosphorylation of the UIM2 domain. *Hum Mol Genet*. 2017 Feb 1;26(3):611-623.
21. Cali T, Frizzarin M, Luoni L, Zonta F, Pantano S, Cruz C, Bonza MC, Bertipaglia I, **Ruzzene** M, De Michelis MI, Damiano N, Marin O, Zanni G, Zanotti G, Brini M, Lopreiato R, Carafoli E. The ataxia related G1107D mutation of the plasma membrane Ca(2+) ATPase isoform 3 affects its interplay with calmodulin and the autoinhibition process. *Biochim Biophys Acta*. 2017 Jan;1863(1):165-173. (BBA-MBD)
22. Marmioli S, Fabbro D, Miyata Y, Pierobon M, **Ruzzene*** M. Phosphorylation, Signaling, and Cancer: Targets and Targeting. *Biomed Res Int*. 2015;2015:601543.
23. Girardi C, Ottaviani D, Pinna LA, **Ruzzene*** M. Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB. *Biomed Res Int*. 2015;2015:185736.
24. Cozza G, Zanin S, Sarno S, Costa E, Girardi C, Ribaldo G, Salvi M, Zagotto G, **Ruzzene*** M, Pinna LA. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity. *Biochem J*. 2015 Nov 1;471(3):415-30.
25. Iori E, **Ruzzene*** M, Zanin S, Sbrignadello S, Pinna LA, Tessari P. Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy. *Growth Factors*. 2015;33(4):259-66.
26. Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, **Ruzzene** M, Delaleu N, Catapano CV, Frew IJ, Alimonti A. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. *Nat Commun*. 2015 Jun 18;6:7227.
27. Zanin S, Sandre M, Cozza G, Ottaviani D, Marin O, Pinna LA, **Ruzzene*** M. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects. *Biochim Biophys Acta*. 2015 Oct;1854(10 Pt B):1694-707. (BBA-PAP)
28. Venerando A, **Ruzzene*** M, Pinna LA. Casein kinase: the triple meaning of a misnomer. *Biochem J*. 2014 Jun 1;460(2):141-56.

29. Girardi C, James P, Zanin S, Pinna LA, **Ruzzene*** M. Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions. *Biochim Biophys Acta*. 2014 Sep;1843(9):1865-74. (BBA-MCR)
30. Cozza G, Zanin S, Determann R, **Ruzzene** M, Kunick C, Pinna LA. Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2). *PLoS One*. 2014 Feb 24;9(2):e89176.
31. Cozza G, Girardi C, Ranchio A, Lolli G, Sarno S, Orzeszko A, Kazimierczuk Z, Battistutta R, **Ruzzene** M, Pinna LA. Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. *Cell Mol Life Sci*. 2014 Aug;71(16):3173-85.
32. Shaik MM, Cendron L, Salamina M, **Ruzzene** M, Zanotti G. Helicobacter pylori periplasmic receptor CeuE (HP1561) modulates its nickel affinity via organic metallophores. *Mol Microbiol*. 2014 Feb;91(4):724-35.
33. Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, **Ruzzene** M, Pinna LA, Semenzato G, Piazza F. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. *J Hematol Oncol*. 2013 Oct 12;6:78.
34. Borgo C, Cesaro L, Salizzato V, **Ruzzene** M, Massimino ML, Pinna LA, Donella-Deana A. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives. *Mol Oncol*. 2013 Dec;7(6):1103-15.
35. Venerando A, Girardi C, **Ruzzene** M, Pinna LA. Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. *Biochem J*. 2013 May 15;452(1):131-7.
36. Cozza G, Sarno S, **Ruzzene** M, Girardi C, Orzeszko A, Kazimierczuk Z, Zagotto G, Bonaiuto E, Di Paolo ML, Pinna LA. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. *Biochim Biophys Acta*. 2013 Jul;1834(7):1402-9. (BBA-PAP)
37. Zanin S, Borgo C, Girardi C, O'Brien SE, Miyata Y, Pinna LA, Donella-Deana A, **Ruzzene*** M. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells. *PLoS One*. 2012;7(11):e49193.
38. Vallese F, Berto P, **Ruzzene** M, Cendron L, Sarno S, De Rosa E, Giacometti GM, Costantini P. Biochemical analysis of the interactions between the proteins involved in the [FeFe]-hydrogenase maturation process. *J Biol Chem*. 2012 Oct 19;287(43):36544-55.
39. Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A, Ave E, Zaffino F, Di Maira G, **Ruzzene** M, Adami F, Zambello R, Pitari MR, Tassone P, Pinna LA, Gurrieri C, Semenzato G, Piazza F. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. *Clin Cancer Res*. 2012 Apr 1;18(7):1888-900.
40. Piazza F, Manni S, **Ruzzene** M, Pinna LA, Gurrieri C, Semenzato G. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. *Leukemia*. 2012 Jun;26(6):1174-9.
41. **Ruzzene*** M, Tosoni K, Zanin S, Cesaro L, Pinna LA. Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects. *Mol Cell Biochem*. 2011 Oct;356(1-2):5-10.
42. Tosoni K, Costa A, Sarno S, D'Alessandro S, Sparla F, Pinna LA, Zottini M, **Ruzzene*** M. The p23 co-chaperone protein is a novel substrate of CK2 in Arabidopsis. *Mol Cell Biochem*. 2011 Oct;356(1-2):245-54.
43. Sarno S, Mazzorana M, Traynor R, **Ruzzene** M, Cozza G, Pagano MA, Meggio F, Zagotto G, Battistutta R, Pinna LA. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A. *Cell Mol Life Sci*. 2012 Feb;69(3):449-60.

44. Stahl S, Branca RM, Efazat G, **Ruzzene** M, Zhivotovsky B, Lewensohn R, Viktorsson K, Lehtio J. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. *J Proteome Res.* 2011 May 6;10(5):2566-78.
45. Accordi B, Espina V, Giordan M, VanMeter A, Milani G, Galla L, **Ruzzene** M, Sciro M, Trentin L, De Maria R, te Kronnie G, Petricoin E, Liotta L, Basso G. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. *PLoS One.* 2010 Oct 21;5(10):e13552.
46. **Ruzzene*** M, Di Maira G, Tosoni K, Pinna LA. Assessment of CK2 constitutive activity in cancer cells. *Methods Enzymol.* 2010;484:495-514.
47. Kreutzer JN, **Ruzzene** M, Guerra B. Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. *BMC Cancer.* 2010 Aug 19;10:440.
48. **Ruzzene*** M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? *Biochim Biophys Acta.* 2010 Mar;1804(3):499-504. (BBA-PAP)
49. Di Maira G, Brustolon F, Pinna LA, **Ruzzene*** M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. *Cell Mol Life Sci.* 2009 Oct;66(20):3363-73.
50. Cozza G, Mazzorana M, Papinutto E, Bain J, Elliott M, di Maira G, Gianoncelli A, Pagano MA, Sarno S, **Ruzzene** M, Battistutta R, Meggio F, Moro S, Zagotto G, Pinna LA. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. *Biochem J.* 2009 Jul 15;421(3):387-95.
51. Peggion C, Lopreiato R, Casanova E, **Ruzzene** M, Facchin S, Pinna LA, Carignani G, Sartori G. Phosphorylation of the *Saccharomyces cerevisiae* Grx4p glutaredoxin by the Bud32p kinase unveils a novel signaling pathway involving Sch9p, a yeast member of the Akt / PKB subfamily. *FEBS J.* 2008 Dec;275(23):5919-33.
52. Cenni V, Bertacchini J, Beretti F, Lattanzi G, Bavelloni A, Riccio M, **Ruzzene** M, Marin O, Arrigoni G, Parnaik V, Wehnert M, Maraldi NM, de Pol A, Cocco L, Marmiroli S. Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells. *J Proteome Res.* 2008 Nov;7(11):4727-35.
53. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, **Ruzzene** M, Di Maira G, Elliott M, Orzeszko A, Cozza G, Meggio F, Pinna LA. The selectivity of inhibitors of protein kinase CK2: an update. *Biochem J.* 2008 Nov 1;415(3):353-65.
54. Di Maira G, Brustolon F, Tosoni K, Belli S, Kramer SD, Pinna LA, **Ruzzene*** M. Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. *Mol Cell Biochem.* 2008 Sep;316(1-2):155-61.
55. Sacchi S, Bernasconi M, Martineau M, Mothet JP, **Ruzzene** M, Pilone MS, Pollegioni L, Molla G. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. *J Biol Chem.* 2008 Aug 8;283(32):22244-56.
56. Dal Pero F, Di Maira G, Marin O, Bortoletto G, Pinna LA, Alberti A, **Ruzzene** M, Gerotto M. Heterogeneity of CK2 phosphorylation sites in the NS5A protein of different hepatitis C virus genotypes. *J Hepatol.* 2007 Dec;47(6):768-76.
57. Facchin S, **Ruzzene*** M, Peggion C, Sartori G, Carignani G, Marin O, Brustolon F, Lopreiato R, Pinna LA. Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt/PKB. *Cell Mol Life Sci.* 2007 Oct;64(19-20):2680-9.
58. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA, **Ruzzene*** M. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. *Oncogene.* 2007 Oct 18;26(48):6915-26.

59. Zottini M, Costa A, De Michele R, **Ruzzene** M, Carimi F, Lo Schiavo F. Salicylic acid activates nitric oxide synthesis in Arabidopsis. *J Exp Bot.* 2007;58(6):1397-405. Epub 2007 Feb 21.
60. Pagano MA, Poletto G, Di Maira G, Cozza G, **Ruzzene** M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. *Chembiochem.* 2007 Jan 2;8(1):129-39.
61. Piazza FA, **Ruzzene** M, Gurrieri C, Montini B, Bonanni L, Chioetto G, Di Maira G, Barbon F, Cabrelle A, Zambello R, Adami F, Trentin L, Pinna LA, Semenzato G. Multiple myeloma cell survival relies on high activity of protein kinase CK2. *Blood.* 2006 Sep 1;108(5):1698-707.
62. Sarno S, **Ruzzene** M, Frascella P, Pagano MA, Meggio F, Zambon A, Mazzorana M, Di Maira G, Lucchini V, Pinna LA. Development and exploitation of CK2 inhibitors. *Mol Cell Biochem.* 2005 Jun;274(1-2):69-76.
63. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, **Ruzzene*** M. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. *Cell Death Differ.* 2005 Jun;12(6):668-77.
64. Barberis M, De Gioia L, **Ruzzene** M, Sarno S, Coccetti P, Fantucci P, Vanoni M, Alberghina L. The yeast cyclin-dependent kinase inhibitor Sic1 and mammalian p27Kip1 are functional homologues with a structurally conserved inhibitory domain. *Biochem J.* 2005 May 1;387(Pt 3):639-47.
65. Pagano MA, Andrzejewska M, **Ruzzene** M, Sarno S, Cesaro L, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Pinna LA. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. *J Med Chem.* 2004 Dec 2;47(25):6239-47.
66. Meggio F, Pagano MA, Moro S, Zagotto G, **Ruzzene** M, Sarno S, Cozza G, Bain J, Elliott M, Deana AD, Brunati AM, Pinna LA. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. *Biochemistry.* 2004 Oct 12;43(40):12931-6.
67. Pagano MA, Meggio F, **Ruzzene** M, Andrzejewska M, Kazimierczuk Z, Pinna LA. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. *Biochem Biophys Res Commun.* 2004 Sep 3;321(4):1040-4.
68. Lopreiato R, Facchin S, Sartori G, Arrigoni G, Casonato S, **Ruzzene** M, Pinna LA, Carignani G. Analysis of the interaction between piD261/Bud32, an evolutionarily conserved protein kinase of *Saccharomyces cerevisiae*, and the Grx4 glutaredoxin. *Biochem J.* 2004 Jan 15;377(Pt 2):395-405.
69. Facchin S, Lopreiato R, **Ruzzene** M, Marin O, Sartori G, Gotz C, Montenarh M, Carignani G, Pinna LA. Functional homology between yeast piD261/Bud32 and human PRPK: both phosphorylate p53 and PRPK partially complements piD261/Bud32 deficiency. *FEBS Lett.* 2003 Aug 14;549(1-3):63-6.
70. Sarno S, de Moliner E, **Ruzzene** M, Pagano MA, Battistutta R, Bain J, Fabbro D, Schoepfer J, Elliott M, Furet P, Meggio F, Zanotti G, Pinna LA. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). *Biochem J.* 2003 Sep 15;374(Pt 3):639-46.
71. Donella-Deana A, Cesaro L, Sarno S, **Ruzzene** M, Brunati AM, Marin O, Vilck G, Doherty-Kirby A, Lajoie G, Litchfield DW, Pinna LA. Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. *Biochem J.* 2003 Jun 15;372(Pt 3):841-9.
72. **Ruzzene*** M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. *Biochem J.* 2002 May 15;364(Pt 1):41-7.

73. Tuhackova Z, Vojtechova M, Hlavacek J, **Ruzzene** M, Sovova V, Pinna LA. Increased activity of c-Src and Csk in fibroblasts transformed by v-src oncogene. *Biochem Biophys Res Commun.* 2002 Jan 18;290(2):790-5.
74. Roher N, Sarno S, Mirò F, **Ruzzene** M, Llorens F, Meggio F, Itarte E, Pinna LA, Plana M. The carboxy-terminal domain of Grp94 binds to protein kinase CK2 alpha but not to CK2 holoenzyme. *FEBS Lett.* 2001 Sep 7;505(1):42-6.
75. Donella-Deana A, Cesaro L, Sarno S, Brunati AM, **Ruzzene** M, Pinna LA. Autocatalytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182. *Biochem J.* 2001 Jul 15;357(Pt 2):563-7.
76. Sarno S, Reddy H, Meggio F, **Ruzzene** M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). *FEBS Lett.* 2001 May 4;496(1):44-8.
77. Meggio F, Negro A, Sarno S, **Ruzzene** M, Bertoli A, Sorgato MC, Pinna LA. Bovine prion protein as a modulator of protein kinase CK2. *Biochem J.* 2000 Nov 15;352 Pt 1:191-6.
78. **Ruzzene*** M, Brunati AM, Sarno S, Marin O, Donella-Deana A, Pinna LA. Ser/Thr phosphorylation of hematopoietic specific protein 1 (HS1): implication of protein kinase CK2. *Eur J Biochem.* 2000 May;267(10):3065-72. (Eur J Biochem changed to FEBS J in 2005)
79. Meggio F, **Ruzzene** M, Sarno S, Pagano MA, Pinna LA. pCMB treatment reveals the essential role of cysteinyl residues in conferring functional competence to the regulatory subunit of protein kinase CK2. *Biochem Biophys Res Commun.* 2000 Jan 7;267(1):427-32.
80. **Ruzzene*** M, Brunati AM, Sarno S, Donella-Deana A, Pinna LA. Hematopoietic lineage cell specific protein 1 associates with and down-regulates protein kinase CK2. *FEBS Lett.* 1999 Nov 12;461(1-2):32-6.
81. Marmiroli S, Bavelloni A, Faenza I, Sirri A, Ognibene A, Cenni V, Tsukada J, Koyama Y, **Ruzzene** M, Ferri A, Auron PE, Toker A, Maraldi NM. Phosphatidylinositol 3-kinase is recruited to a specific site in the activated IL-1 receptor I. *FEBS Lett.* 1998 Oct 30;438(1-2):49-54.
82. Brunati AM, Pinna LA, Bergantino E, **Ruzzene** M, Cirri P, Ramponi G, Donella-Deana A. Src homology-2 domains protect phosphotyrosyl residues against enzymatic dephosphorylation. *Biochem Biophys Res Commun.* 1998 Feb 24;243(3):700-5.
83. Donella-Deana A, Cesaro L, **Ruzzene** M, Brunati AM, Marin O, Pinna LA. Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity. *Biochemistry.* 1998 Feb 3;37(5):1438-46
84. **Ruzzene*** M, Songyang Z, Marin O, Donella-Deana A, Brunati AM, Guerra B, Agostinis P, Cantley LC, Pinna LA. Sequence specificity of C-terminal Src kinase (CSK)--a comparison with Src-related kinases c-Fgr and Lyn. *Eur J Biochem.* 1997 Jun 1;246(2):433-9. (Eur J Biochem changed to FEBS J in 2005)
85. **Ruzzene*** M, Brunati AM, Donella-Deana A, Marin O, Pinna LA. Specific stimulation of c-Fgr kinase by tyrosine-phosphorylated (poly)peptides—possible implication in the sequential mode of protein phosphorylation. *Eur J Biochem.* 1997 May 1;245(3):701-7. (Eur J Biochem changed to FEBS J in 2005)
86. Pinna LA, **Ruzzene*** M. How do protein kinases recognize their substrates? *Biochim Biophys Acta.* 1996 Dec 12;1314(3):191-225. (BBA-MCR)
87. Macino B, Zambon A, Milan G, Cabrelle A, **Ruzzene** M, Rosato A, Mandruzzato S, Quintieri L, Zanovello P, Collavo D. CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. *Biochem Biophys Res Commun.* 1996 Sep 24;226(3):769-76.
88. Brunati AM, James P, Guerra B, **Ruzzene** M, Donella-Deana A, Pinna LA. The spleen protein-tyrosine kinase TPK-IIB is highly similar to the catalytic domain of p72syk. *Eur J Biochem.* 1996 Sep 1;240(2):400-7 (Eur J Biochem changed to FEBS J in 2005)

89. **Ruzzene*** M, Brunati AM, Marin O, Donella-Deana A, Pinna LA. SH2 domains mediate the sequential phosphorylation of HS1 protein by p72syk and Src-related protein tyrosine kinases. *Biochemistry*. 1996 Apr 23;35(16):5327-32.
90. Agostinis P, Donella-Deana A, Van Hoof C, Cesaro L, Brunati AM, **Ruzzene** M, Merlevede W, Pinna LA, Goris J. A comparative study of the phosphotyrosyl phosphatase specificity of protein phosphatase type 2A and phosphotyrosyl phosphatase type 1B using phosphopeptides and the phosphoproteins p50/HS1, c-Fgr and Lyn. *Eur J Biochem*. 1996 Mar 1;236(2):548-57. (Eur J Biochem changed to FEBS J in 2005)
91. Donella-Deana A, James P, Staudenmann W, Cesaro L, Marin O, Brunati AM, **Ruzzene** M, Pinna LA. Isolation from spleen of a 57-kDa protein substrate of the tyrosine kinase Lyn. Identification as a protein related to protein disulfide-isomerase and localisation of the phosphorylation sites. *Eur J Biochem*. 1996 Jan 15;235(1-2):18-25. (Eur J Biochem changed to FEBS J in 2005)
92. Meggio F, Donella Deana A, **Ruzzene** M, Brunati AM, Cesaro L, Guerra B, Meyer T, Mett H, Fabbro D, Furet P, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. *Eur J Biochem*. 1995 Nov 15;234(1):317-22. (Eur J Biochem changed to FEBS J in 2005)
93. Brunati AM, Donella-Deana A, **Ruzzene** M, Marin O, Pinna LA. Site specificity of p72syk protein tyrosine kinase: efficient phosphorylation of motifs recognized by Src homology 2 domains of the Src family. *FEBS Lett*. 1995 Jun 26;367(2):149-52.
94. Brunati AM, **Ruzzene** M, James P, Guerra B, Pinna LA. Hierarchical phosphorylation of a 50-kDa protein by protein tyrosine kinases TPK-IIB and C-Fgr, and its identification as HS1 hematopoietic-lineage cell-specific protein. *Eur J Biochem*. 1995 Apr 1;229(1):164-70. (Eur J Biochem changed to FEBS J in 2005)
95. **Ruzzene*** M, James P, Brunati AM, Donella-Deana A, Pinna LA. Regulation of c-Fgr protein kinase by c-Src kinase (CSK) and by polycationic effectors. *J Biol Chem*. 1994 Jun 3;269(22):15885-91.
96. Caffieri S, **Ruzzene** M, Guerra B, Frank S, Vedaldi D, Dall'Acqua F. Psoralen-fatty acid cycloadducts activate protein kinase C (PKC) in human platelets. *J Photochem Photobiol B*. 1994 Mar;22(3):253-6.
97. Donella-Deana A, Krinks MH, **Ruzzene** M, Klee C, Pinna LA. Dephosphorylation of phosphopeptides by calcineurin (protein phosphatase 2B). *Eur J Biochem*. 1994 Jan 15;219(1-2):109-17. (Eur J Biochem changed to FEBS J in 2005)
98. Perich JW, **Ruzzene** M, Pinna LA, Reynolds EC. Efficient Fmoc/solid-phase peptide synthesis of O-phosphotyrosyl-containing peptides and their use as phosphatase substrates. *Int J Pept Protein Res*. 1994 Jan;43(1):39-46.
99. **Ruzzene*** M, Donella-Deana A, Marin O, Perich JW, Ruzza P, Borin G, Calderan A, Pinna LA. Specificity of T-cell protein tyrosine phosphatase toward phosphorylated synthetic peptides. *Eur J Biochem*. 1993 Jan 15;211(1-2):289-95. (Eur J Biochem changed to FEBS J in 2005)
100. **Ruzzene*** M, Vianello F, Donella-Deana A, Deana R. Purification and characterization of two casein kinases from ejaculated bovine spermatozoa. *J Biochem*. 1992 Dec;112(6):768-74
101. **Ruzzene*** M, Francesconi M, Donella-Deana A, Alexandre A, Deana R. The antioxidant butylated hydroxytoluene (BHT) inhibits the dioctanoylglycerol-evoked platelet response but potentiates that elicited by ionomycin. *Arch Biochem Biophys*. 1992 May 1;294(2):724-30.
102. **Ruzzene*** M, Francesconi M, Cavallini L, Battistella L, Deana R. Inhibition of thrombin-induced platelet activation by dioctanoylglycerol pretreatment is not correlated with the 47 kDa protein phosphorylation. *Second Messengers Phosphoproteins*. 1992;14(1-2):11-9.

103. Doni MG, Deana R, Padoin E, **Ruzzene** M, Alexandre A. Platelet activation by diacylglycerol or ionomycin is inhibited by nitroprusside. *Biochim Biophys Acta*. 1991 Sep 24;1094(3):323-9. (BBA-MCR)
104. **Ruzzene*** M, Donella-Deana A, Alexandre A, Francesconi MA, Deana R. The antioxidant butylated hydroxytoluene stimulates platelet protein kinase C and inhibits subsequent protein phosphorylation induced by thrombin. *Biochim Biophys Acta*. 1991 Aug 13;1094(1):121-9. (BBA-MCR)
105. Cavallini L, Francesconi MA, **Ruzzene** M, Valente M, Deana R. A procedure allowing measurement of cytosolic Ca²⁺ in rat platelets. Inhibition of a plasma lipoprotein on fura 2-AM loading. *Thromb Res*. 1991 Jul 1;63(1):47-57.
106. Zoccarato F, **Ruzzene** M, Cavallini L, Doni MG, Francesconi MA, Deana R, Alexandre A. Platelet responses promoted by the activation of protein kinase C or the increase of cytosolic Ca²⁺ are potentiated by adrenaline. Effects of cAMP and staurosporine. *Biochim Biophys Acta*. 1991 Mar 19;1092(1):72-8. (BBA-MCR)
107. Deana R, **Ruzzene** M, Doni MG, Zoccarato F, Alexandre A. Cyclic GMP and nitroprusside inhibit the activation of human platelets by fluoroaluminate. *Biochim Biophys Acta*. 1989 Nov 20;1014(2):203-6. (BBA-MCR)
108. Deana R, **Ruzzene** M, Cavallini L, Francesconi M, Rigoni F. Effects of calcium chelators, divalent cations and sulfhydryl reagents on calcium uptake and motility of bovine spermatozoa. *Cell Calcium*. 1988 Jun;9(3):121-8.

Book chapters

109. Girardi C, **Ruzzene*** M. CK2 function in the regulation of Akt pathway (2014) in press in *Protein kinase CK2 cellular function in normal and disease states*, K. Ahmed, O.-G. Issinger, R. Szyszka eds, Springer
110. **Ruzzene*** M. Addiction of cancer cells to CK2: survival at all costs or Achilles' heel? (2012) p. 305-318, in *Protein Kinase CK2*, Wiley-Blackwell, L.A. Pinna ed., Ames, Iowa, USA
111. **Ruzzene*** M, Pinna LA. Assay of protein kinases and phosphatases using specific peptide substrates (1999) p. 221-253, in *Protein Phosphorylation (Second edition) A Practical Approach*, Oxford University Press, D.G. Hardie ed., Dundee, Scotland, UK
112. **Ruzzene*** M, Lorenzen JA, Donella-Deana A, Marin O, Perich JW, Fischer EH, Pinna LA. Specificity of the truncated form of human T-cell protein tyrosine phosphatase toward phosphorylated synthetic peptides (1993) p. 107-110, in *NATO ASI Series Vol. H, Tyrosine Phosphorylation /Dephosphorylation and Downstream Signalling*, L.M.G. Heilmeyer Jr ed., Sperling-Verlag Berlin Heidelberg, Germany
113. Donella-Deana A, Brunati AM, **Ruzzene** M, Pinna LA. Polylysine activates a splenic tyrosine kinase encoded by fgr protooncogene (1993) p. 135-138, in *NATO ASI Series Vol. H, Tyrosine Phosphorylation /Dephosphorylation and Downstream Signalling*, L.M.G. Heilmeyer Jr ed., Sperling-Verlag Berlin Heidelberg, Germany

Mania Ruzzene